Evidence map›Paper›PMID 40705857›Full record

ReviewDialogues in clinical neuroscience2025

Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force.

Pierre A Geoffroy, Laura Palagini, Tone E G Henriksen, Patrice Bourgin, Corrado Garbazza, Claude Gronfier, Yuichi Esaki, Diego C Fernandez, Raymond W Lam, Heon-Jeong Lee and 11 more

Abstract readReview
In one paragraph

Review in Dialogues in clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Therapeutic prospects of bright light therapy in addictive disorders: a scoping review.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Pierre A GeoffroyDépartement de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, Paris, France.ORCID 0000-0001-9121-209X
Laura PalaginiDepartment of Neuroscience, Psychiatric Section, University of Pisa, Azienda Ospedaliera Universitaria Pisana (AUOP), Pisa, Italy.ORCID 0000-0003-1676-629X
Tone E G HenriksenDivision of Mental Health Care, Valen Hospital, Department of Research and Innovation, Fonna Health Trust, Haugesund, Norway.ORCID 0000-0002-5343-342X
Patrice BourginInstitute for Cellular and Integrative Neurosciences, CNRS UPR 3212 & Strasbourg University, Strasbourg, France.ORCID 0000-0003-2268-5840
Corrado GarbazzaCentre for Chronobiology, University Psychiatric Clinics (UPK), Basel, Switzerland.ORCID 0000-0002-8606-2944
Claude GronfierLyon Neuroscience Research Center (CRNL), Inserm U1028, CNRS UMR5292, Université Lyon 1, Bron, France.ORCID 0000-0002-6549-799X
Yuichi EsakiDepartment of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan.ORCID 0000-0001-5165-6171
Diego C FernandezDivision of Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center. Department of Ophthalmology, College of Medicine, University of Cincinnati, Cincinnati, USA.ORCID 0000-0002-4363-1318
Raymond W LamDepartment of Psychiatry, University of British Columbia, Vancouver, Canada.ORCID 0000-0001-7142-4669
Heon-Jeong LeeDepartment of Psychiatry, Korea University College of Medicine, Seoul, Republic of Korea; Chronobiology Institute, Korea University, Seoul, Republic of Korea.ORCID 0000-0002-9560-2383
Michel LejoyeuxDépartement de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, Paris, France.ORCID 0000-0002-3512-9694
Julia MaruaniDépartement de psychiatrie et d'addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hôpital Bichat - Claude Bernard, Paris, France.ORCID 0000-0002-2002-6051
Klaus MartinyMental Health Centre Copenhagen, Mental Health Services of the Capital Region of Denmark and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-7317-5958
Greg MurrayCentre for Mental Health and Brain Sciences, Swinburne University, Melbourne, Australia.ORCID 0000-0003-1372-3489
Rixt F Riemersma-Van Der LekMental Health Services Drenthe, Assen, the Netherlands.
Philipp RitterDepartment of Psychiatry and Psychotherapy. Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.ORCID 0000-0003-4286-5830
Peter F J SchulteMental Health Service Noord-Holland-Noord, Alkmaar, Netherlands.ORCID 0000-0003-4931-3393
Daniel J SmithDivision of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK.ORCID 0000-0001-6294-1269
Michael TermanCenter For Environmental Therapeutics, Worcester, MA, USA.
Jamie M ZeitzerDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.ORCID 0000-0001-6174-5282
Dorothy K SitFeinberg School of Medicine, Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago, IL, USA.ORCID 0000-0001-8837-3343

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force conducted a comprehensive review to deliver concise evidence-based recommendations on the use of bright light therapy (BLT) for bipolar disorder (BD). Adjunctive BLT is likely an efficacious acute treatment for bipolar depression as implicated by higher quality evidence. The position of maintenance BLT for relapse prevention awaits further investigation. Protocols of effective BLT in BD are similar to parameters indicated for treatment of seasonal and non-seasonal major depressive disorder. Anti-manic prophylaxis (especially for BD-I) and clinical monitoring are recommended with initiation of and ongoing light treatment. Administer BLT daily, preferably in the morning or at mid-day. If mornings are prohibitive, then mid-day exposure, implemented to avoid excessively early wake times, is an acceptable alternative. Informed by the literature, target 30 min/day of BLT exposure. Patients wary of emergent hypomania or partial responders, can initiate 15 min/day and increase by 15 min each week to full response (or 30-60 min/day by the fourth week). Consider patient centred outcome assessments to evaluate mood response, safety and side effects. Clinical improvement is typically observed within 1-2 weeks, with response/remission expected by 4-6 weeks. Integration of BLT with other chronotherapeutic strategies may enhance long-term efficacy.

Indexed as

Bipolar DisorderChronotherapyPhototherapyChronobiology PhenomenaCircadian RhythmHumansSocieties, MedicalBipolar disorderchronotherapydepressionlight therapyphototherapyseasonal affective disorder

Identifiers

PMID40705857
PMCPMC12291220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.